AstraZeneca, FibroGen give China bragging rights to first-in-class anemia drug approval
admin 18th December 2018 Uncategorised 0It is a rare event, if not a singular one in the biopharma world: A first-in-class drug developed by multinational pharma companies was filed first—and now approved first—in China, well before the U.S., EU or Japan.
More: AstraZeneca, FibroGen give China bragging rights to first-in-class anemia drug approval
Source: fierce